Search Results | Blood | American Society of Hematology

1-20 of 91

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

DOI: https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece

Blood (2018) 131 (8): 855–863.

DOI: https://doi.org/10.1182/blood-2017-08-797886

Published: 2018

Includes: Supplemental data

Journal Articles

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood (2018) 131 (3): 301–310.

DOI: https://doi.org/10.1182/blood-2017-07-795047

Published: 2018

Includes: Supplemental data

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

DOI: https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

DOI: https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

DOI: https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Final Analysis of Overall Survival from the First Trial

Blood (2016) 128 (22): 241.

DOI: https://doi.org/10.1182/blood.V128.22.241.241

Published: 2016

Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD

Blood (2016) 128 (22): 1795.

DOI: https://doi.org/10.1182/blood.V128.22.1795.1795

Published: 2016

Journal Articles

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Anca Prica, MD, Vinita Dhir, Nuchanan Areethamsirikul, MD, Christine Chen, MD, Donna Reece, MD, Suzanne Trudel, MD, Rodger Tiedemann, MBChB, PhD, Vishal Kukreti, MD

Blood (2016) 128 (22): 1184.

DOI: https://doi.org/10.1182/blood.V128.22.1184.1184

Published: 2016

Journal Articles

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Sara Farshchi Zarabi, MD, Esther Masih-Khan, PhD, Christine Chen, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 5821.

DOI: https://doi.org/10.1182/blood.V128.22.5821.5821

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

DOI: https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

DOI: https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

DOI: https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Ming Han, Alli Murugesan, Nizar J. Bahlis, Kevin Song, Darrell White, Christine Chen, Matthew D. Seftel, Kang Howsen-Jan, Donna Reece, Keith Stewart, Yagang Xie, Annette E. Hay, Lois Shepherd, Marina Djurfeldt, Liting Zhu, Ralph M. Meyer, Bingshu E. Chen, Tony Reiman

Blood (2016) 128 (5): 732–735.

DOI: https://doi.org/10.1182/blood-2016-06-716902

Published: 2016

Includes: Supplemental data

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

DOI: https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite TMÂ chain (HLC) Normalization

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhDMSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Prica Anca, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul

Blood (2015) 126 (23): 1982.

DOI: https://doi.org/10.1182/blood.V126.23.1982.1982

Published: 2015

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

DOI: https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Bethany E Monteith, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Christine Chen, MD, Anca Prica, MD, Donna Reece, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2015) 126 (23): 5361.

DOI: https://doi.org/10.1182/blood.V126.23.5361.5361

Published: 2015

Journal Articles

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Majed Alahmadi, MBBS, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Limore Arones, Christine Chen, MD, Vishal Kukreti, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD, Donna Reece

Blood (2015) 126 (23): 1842.

DOI: https://doi.org/10.1182/blood.V126.23.1842.1842

Published: 2015

Journal Articles

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Sara Farshchi-Zarabi, MD, Gurdeep Parmar, MD, Esther Masih-Khan, PhD, Sophia Farooki, MD FRCPC, Christine Chen, MD FRCPC, Vishal Kukreti, MD FRCPC, Anca Prica, MD FRCPC, Rodger Tiedemann, MBChB, FRCPC, PhD, Suzanne Trudel, MD, Donna Reece

Blood (2015) 126 (23): 3176.

DOI: https://doi.org/10.1182/blood.V126.23.3176.3176

Published: 2015

2 3 4 5

NARROW

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Final Analysis of Overall Survival from the First Trial

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only